HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells.
We previously reported on a panel of HIV-1 clade B envelope (Env) proteins isolated from a patient treated with the CCR5 antagonist aplaviroc (APL) that were drug resistant. These Envs used the APL-bound conformation of CCR5, were cross resistant to other small-molecule CCR5 antagonists, and were isolated from the patient's pretreatment viral quasispecies as well as after therapy. We analyzed viral and host determinants of resistance and their effects on viral tropism on primary CD4(+) T cells. The V3 loop contained residues essential for viral resistance to APL, while additional mutations in gp120 and gp41 modulated the magnitude of drug resistance. However, these mutations were context dependent, being unable to confer resistance when introduced into a heterologous virus. The resistant virus displayed altered binding between gp120 and CCR5 such that the virus became critically dependent on the N' terminus of CCR5 in the presence of APL. In addition, the drug-resistant Envs studied here utilized CCR5 very efficiently: robust virus infection occurred even when very low levels of CCR5 were expressed. However, recognition of drug-bound CCR5 was less efficient, resulting in a tropism shift toward effector memory cells upon infection of primary CD4(+) T cells in the presence of APL, with relative sparing of the central memory CD4(+) T cell subset. If such a tropism shift proves to be a common feature of CCR5-antagonist-resistant viruses, then continued use of CCR5 antagonists even in the face of virologic failure could provide a relative degree of protection to the T(CM) subset of CD4(+) T cells and result in improved T cell homeostasis and immune function.
Pfaff
Jennifer M
JM
Department of Microbiology, University of Pennsylvania, 3610 Hamilton Walk, Philadelphia, PA 19104, USA.
Wilen
Craig B
CB
Harrison
Jessamina E
JE
Demarest
James F
JF
Lee
Benhur
B
Doms
Robert W
RW
Tilton
John C
JC
D019380:Anti-HIV Agents / Q000494:pharmacology*; D001565:Benzoates / Q000494:pharmacology; D065100:CCR5 Receptor Antagonists; D015496:CD4-Positive T-Lymphocytes / Q000821:virology*; D054659:Diketopiperazines; D024882:Drug Resistance, Viral; D015699:HIV Envelope Protein gp120 / Q000235:genetics; D015700:HIV Envelope Protein gp41 / Q000235:genetics; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D020125:Mutation, Missense; D010879:Piperazines / Q000494:pharmacology; D019713:Receptors, CCR5 / Q000502:physiology*; D015728:Receptors, HIV / Q000037:antagonists & inhibitors / Q000502:physiology*; D013141:Spiro Compounds / Q000494:pharmacology; D056189:Viral Tropism; D053585:Virus Attachment
D019380:Anti-HIV Agents; D001565:Benzoates; D065100:CCR5 Receptor Antagonists; D054659:Diketopiperazines; D015699:HIV Envelope Protein gp120; D015700:HIV Envelope Protein gp41; D010879:Piperazines; D019713:Receptors, CCR5; D015728:Receptors, HIV; D013141:Spiro Compounds; C514793:gp120 protein, Human immunodeficiency virus 1; C499671:aplaviroc
J Biol Chem. 2006 May 5;281(18):12688-98
16476734
J Virol. 2009 Nov;83(21):11016-26
19692480
J Virol. 2002 Nov;76(21):10791-800
12368322
Antimicrob Agents Chemother. 2000 Jan;44(1):51-6
10602722
Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):5215-20
10220446
J Virol. 2001 Jun;75(12):5541-9
11356961
AIDS. 2005 Sep 23;19(14):1443-8
16135896
PLoS Pathog. 2009 Aug;5(8):e1000548
19680536
Cell. 1998 May 29;93(5):681-4
9630213
J Virol. 2006 May;80(10):4909-20
16641282
Cell. 1996 Nov 1;87(3):437-46
8898197
Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):395-400
11782552
Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5318-23
19289833
J Virol. 1998 Apr;72(4):3464-8
9525683
J Virol. 2008 Aug;82(16):8210-4
18495779
Nature. 1996 Nov 14;384(6605):184-7
8906796
J Virol. 1998 Feb;72(2):1160-4
9445013
Curr Opin HIV AIDS. 2009 Mar;4(2):82-7
19339945
Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10598-602
12960367
Virology. 2006 May 25;349(1):41-54
16494916
J Infect Dis. 2007 Jul 15;196(2):304-12
17570119
AIDS Res Hum Retroviruses. 1998 May 1;14(7):607-17
9591715
Proc Natl Acad Sci U S A. 2000 May 9;97(10):5639-44
10779565
Nature. 1999 Oct 14;401(6754):708-12
10537110
Antimicrob Agents Chemother. 2009 Mar;53(3):1124-31
19075068
J Virol. 2009 Dec;83(23):12151-63
19776131
Antiviral Res. 2010 Jan;85(1):91-100
19683546
J Virol. 2004 Mar;78(6):2790-807
14990699
Antimicrob Agents Chemother. 2007 Feb;51(2):707-15
17116673
Virology. 2009 May 10;387(2):296-302
19303620
Mol Pharmacol. 2005 Apr;67(4):1268-82
15644495
Science. 1998 Jun 19;280(5371):1949-53
9632396
Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12718-23
11606733
Nature. 1998 Jun 18;393(6686):648-59
9641677
J Exp Med. 2007 Sep 3;204(9):2171-85
17724130
AIDS Res Hum Retroviruses. 2000 May 20;16(8):741-9
10826481
Virology. 2008 Apr 10;373(2):387-99
18190945
J Biol Chem. 1999 Apr 2;274(14):9617-26
10092648
PLoS Pathog. 2007 Aug 24;3(8):e117
17722977
AIDS. 2004 Apr 9;18(6):837-48
15060431
Virology. 2000 Jun 5;271(2):240-7
10860877
AIDS Res Hum Retroviruses. 2010 Jan;26(1):13-24
20055594
J Virol. 2003 May;77(9):5201-8
12692222
Science. 2006 Jun 9;312(5779):1530-3
16763152
J Virol. 2002 Sep;76(17):8953-7
12163614
Science. 2007 Sep 28;317(5846):1930-4
17901336
Virology. 2005 Jul 20;338(1):182-99
15935415
Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1925-30
9050881
Nature. 2005 Feb 24;433(7028):834-41
15729334
Biochim Biophys Acta. 2003 Jul 11;1614(1):36-50
12873764
Antiviral Res. 2001 May;50(2):95-115
11369431
J Virol. 2007 Mar;81(5):2359-71
17182681
Virology. 2007 Apr 25;361(1):212-28
17166540
Retrovirology. 2006 Aug 17;3:52
16916447
J Mol Biol. 2008 Sep 12;381(4):956-74
18590744
J Virol. 1997 Sep;71(9):6305-14
9261347